Amgen to face shareholder suit
From Times Wire Services
Amgen Inc. must defend a lawsuit over claims that it misled investors about safety issue with its top-selling anemia drugs, Epogen and Aranesp.
A U.S. district judge in Los Angeles denied Amgen’s request to dismiss a consolidated shareholders’ complaint.
Shareholders say Thousand Oaks-based Amgen artificially inflated its stock price from April 2004 to May 2007 by making false statements about the drugs’ safety and by marketing them for uses not approved by the Food and Drug Administration.
